SCFD2 Inhibitors
SCFD2 inhibitors are a class of chemical compounds that target the SCFD2 protein, which plays a key role in a specific cellular process. The SCFD2 protein, or Sec1 family domain containing 2, is involved in the regulation of intracellular transport. This protein is a part of a larger family of proteins that are crucial for the vesicle-mediated transport system within cells, a system that is essential for the proper sorting and delivery of proteins and lipids to their destined locations. By inhibiting SCFD2, these compounds can affect the machinery that dictates the traffic within the cell, thereby influencing the distribution and function of cellular components. The precise mechanism of action of SCFD2 inhibitors involves the disruption of the interaction between SCFD2 and other proteins or molecules it normally binds with, which is a critical step in the vesicle transport pathway.
The specificity of SCFD2 inhibitors lies in their ability to selectively bind to the SCFD2 protein, thereby modulating its activity. In doing so, they are able to alter the dynamics of vesicle formation, movement, and fusion with target membranes. This specificity is achieved through the chemical structure of the inhibitors, which is designed to closely mimic or compete with the natural substrates or binding partners of the SCFD2 protein. Research into SCFD2 inhibitors often delves into the biophysical and biochemical traits of these compounds to understand how they achieve their high affinity for the SCFD2 protein and how they induce conformational changes upon binding. The study of SCFD2 inhibitors also encompasses the exploration of their selectivity and potency, as these characteristics are crucial for their precise effect on cellular pathways. By understanding the interaction at a molecular level, researchers can elucidate the role of SCFD2 in cellular processes and its impact on the intracellular transport system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting the PI3K/AKT pathway, it may indirectly affect SCFD2 function, as this pathway is involved in vesicle-mediated transport and membrane trafficking, processes in which SCFD2 is potentially implicated. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is a fungal metabolite that disrupts the Golgi apparatus structure by inhibiting ADP-ribosylation factor (ARF). As SCFD2 is thought to be involved in vesicle trafficking from the Golgi, inhibition of ARF by Brefeldin A could impede SCFD2-mediated transport processes. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering intracellular pH and cation exchange. This disruption can indirectly inhibit SCFD2 by affecting vesicular transport and secretion pathways where SCFD2 may play a role. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a GTPase essential for clathrin-mediated endocytosis. If SCFD2 functions in concert with endocytic pathways, dynamin inhibition by Dynasore would indirectly impair SCFD2's role in this process. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is crucial for vesicle transport along the cytoskeleton. As such, it could indirectly affect SCFD2 function if SCFD2 is associated with microtubule-dependent transport mechanisms. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D is an inhibitor of actin polymerization. If SCFD2 activity is related to actin cytoskeleton dynamics, such as in vesicle movement or membrane remodeling, Cytochalasin D could indirectly inhibit SCFD2's function. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF. By inhibiting GBF1, Golgicide A can disrupt ARF-dependent trafficking, potentially affecting SCFD2-related transport processes from the Golgi. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation in the ER. This disrupts protein folding and Golgi processing, which could indirectly affect SCFD2 if its function is related to glycoprotein trafficking or processing. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1, an exocyst complex inhibitor, could indirectly affect SCFD2 if it is involved in the tethering of transport vesicles to the plasma membrane, a process regulated by the exocyst complex. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, disrupting microtubule dynamics. Indirectly, this could affect SCFD2 by altering the vesicular transport mechanisms that might depend on intact microtubules. | ||||||